Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | PHASE2 | RECRUITING | 270 | — | — | Apr 11, 2025 | Dec 1, 2026 | Apr 14, 2026 | 49 | United States, Belgium +6 |
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first.
| Arm | Type | Description |
|---|---|---|
| Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab | EXPERIMENTAL | In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
| Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab | EXPERIMENTAL | In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
| Arm C: Relacorilant in Combination with Nab-Paclitaxel | EXPERIMENTAL | In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
| Name | Type | Description |
|---|---|---|
| Relacorilant 150 mg once daily (QD) | DRUG | Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion. |
| Nab-paclitaxel 80 mg/m^2 | DRUG | Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
| Bevacizumab 10 mg/kg | DRUG | Bevacizumab is administered as IV infusion on Days 1 and 15. |
Inclusion Criteria: Arms A and B * Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma * Arm A Only: Platinum-resistant disease * Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) i...